Clinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma
Neuroblastoma is a pediatric cancer of the developing sympathetic nervous system. High-risk neuroblastoma patients typically undergo an initial remission in response to treatment, followed by recurrence of aggressive tumors that have become refractory to further treatment. The need for biomarkers th...
Main Authors: | Peter Utnes, Cecilie Løkke, Trond Flægstad, Christer Einvik |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-03-01
|
Series: | Cancer Informatics |
Online Access: | https://doi.org/10.1177/1176935119832910 |
Similar Items
-
Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma
by: Tømte Ellen, et al.
Published: (2011-01-01) -
Integrative discovery of treatments for high-risk neuroblastoma
by: Elin Almstedt, et al.
Published: (2020-01-01) -
Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma
by: Xao X. Tang, et al.
Published: (2021-04-01) -
Android Apps and Permissions: Security and Privacy Risks
by: Boksasp, Trond, et al.
Published: (2012) -
Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis
by: Marine De Paoli, et al.
Published: (2016-01-01)